Medtronic Completes MiniMed Separation as Analysts Split on Valuation
Published on 10/12/2026 at 14:10 | Editorial boerse-global.de
Medtronic has closed the books on its MiniMed divestiture, setting the stage for a leaner device maker whose investment case now rests on how quickly a deep pipeline of regulatory wins converts into billable revenue.
The exchange offer expired last Friday, with Medtronic fixing the final swap ratio at 4.5939 MiniMed shares for each Medtronic common share tendered. The offering covered as many as 225,361,295 MiniMed shares, completing the company's exit from the diabetes business. The stock barely registered the milestone, trading at EUR 79.10 on the day, up 0.1%, for a market capitalization of EUR 100.18 billion.
Barclays Steps to the Sidelines
Analysts have drawn different conclusions from the reshaped portfolio. Barclays initiated coverage about a week ago with an Equal Weight rating and a USD 95 price target, a neutral stance that captures the current wait-and-see mood. TD Cowen took the opposite tack on September 30, reiterating its Buy recommendation and lifting its target to USD 110 from USD 100.
The divergence reflects a genuine open question: whether management's overhaul translates into accelerating earnings, or whether the market must keep waiting. Medtronic's reach remains vast — the company reported treating more than 82 million patients worldwide in its fiscal 2026 report — but scale alone does not settle the margin debate.
R&D Spending Meets a Thick Approval Queue
What investors are watching now is the commercial efficiency of a hefty research budget. Medtronic booked USD 2.9 billion in research and development spending for fiscal 2026, a figure that keeps the company technologically current but weighs on near-term margins while new devices work their way through sales channels.
Should investors sell immediately? Or is it worth buying Medtronic?
The offsetting asset is volume: more than 315 product approvals in key markets over the same period. The pace at which those clearances become high-margin revenue streams will determine whether the valuation can climb beyond its present level.
Reimbursement Wins Set Up a 2028 Payoff
Regulatory groundwork from recent months provides the medium-term leverage. The American Medical Association granted Category I CPT billing codes for the Symplicity Spyral and Altaviva systems roughly a week ago, with those codes taking effect in January 2028. That locks in predictable reimbursement pathways within the US healthcare system.
Clinical momentum is building alongside. Medtronic presented 24-month results from the exploratory TITAN-2 study of its Altaviva tibial neuromodulation system, showing sustained improvements in nocturia. For the subsequent post-market ENDURANCE trial, the company named Ariana L. Smith as national principal investigator; the study will follow 170 implanted patients across up to 30 US sites over five years.
In ENT surgery, a US market debut is approaching. First clinical cases using the ApexCut EM blades with the Stealth AXiS navigation system are slated for later in 2026, following FDA clearance.
The Gap Between Investment and Payment
A realistic risk sits on the other side of the ledger: the lag between spending and broad reimbursement. The Category I codes for Altaviva and Symplicity Spyral do not kick in until January 2028, leaving sales teams reliant on interim arrangements and labor-intensive case-by-case reviews that could cap US growth in the meantime.
Rolling out new instruments such as the navigated ApexCut blades also demands significant training resources and operating-room changeover time. If surgeons adopt the new systems more slowly than planned, revenue could undershoot expectations. And because Medtronic keeps committing large sums to programs like ENDURANCE, any delay in market penetration would hit operating returns directly.
What Moves the Stock From Here
As long as the shares hold around EUR 79.00, the groundwork for a gradual re-rating stays intact. A shift in sentiment driven by product launch delays, however, could leave the stock stuck in its narrow trading band. A 0.7% gain over the past seven days suggests investors are biding their time.
The next concrete catalyst is the first US clinical use of the ApexCut EM blades later in 2026, which will show how quickly Medtronic can monetize cleared innovations in everyday hospital practice. Further out, attention turns to ENDURANCE trial progress, which must bridge the period until the new reimbursement codes take effect in January 2028.
Ad
Medtronic Stock: New Analysis - 12 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
